Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Nov 1;6(11):2700–2712.

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

AJCR Copyright © 2016

PMC Copyright notice

Correlation between DLK1 expression and the efficacy of imatinib adjuvant treatment in intermediate- and high-risk GIST patients. A: In the test cohort, among 74 DLK1-negative intermediate- and high-risk GIST patients, DFS of the patients with imatinib adjuvant treatment was significantly higher than that of the patients without imatinib adjuvant treatment (P = 0.022). B: In the validation cohort, among 41 DLK1-negative intermediate- and high-risk GIST patients, DFS of the patients with imatinib adjuvant treatment was significantly higher than that of the patients without imatinib adjuvant treatment (P = 0.046). C: In the test cohort, among 67 DLK1-positive intermediate- and high-risk GIST patients, there was no significant difference in DFS between the groups with or without imatinib adjuvant treatment (P = 0.612). D: In the validation cohort, among 46 DLK1-positive intermediate- and high-risk GIST patients, there was no significant difference in DFS between the groups with or without imatinib adjuvant treatment (P = 0.704).